Clinically relevant, confirmed CMV resistance substitution mutations occurring in UL97, identified by recombinant phenotyping
| Codon number . | Wild-type . | Mutant . | GCV ratio* . | References . |
|---|---|---|---|---|
| Canonical mutations | ||||
| 460 | M | I | 5 | 47,72,80,142,152,,,,,,,,,,-163 |
| 460 | M | V | 8.3 | 43,47,80,82,83,142,154,-156,159,-161,164,,,,-169 |
| 520 | H | Q | 10 | 47,72,83,142,154,155,159,161,164,165,169,-171 |
| 592 | C | G | 2.9 | 72,80,82,83,142,153,154,159,-161,163,165,166,172,173 |
| 594 | A | V | 8.3 | 43,72,80,82,83,152,,,-156,158,,-161,164,-166,171,173 |
| 595 | L | S | 9.2 | 43,72,80,82,83,153,-155,158,,,,,,,-166 |
| 603 | C | W | 8 | 72,80,83,142,153,-155,159,-161,163,164,171,172,174,175 |
| Other clinically relevant substitution mutations | ||||
| 595 | L | F | 15.7 | 72,156,161,175 |
| 595 | L | W | 5.1 | 72,154,155,159,-161,175 |
| Codon number . | Wild-type . | Mutant . | GCV ratio* . | References . |
|---|---|---|---|---|
| Canonical mutations | ||||
| 460 | M | I | 5 | 47,72,80,142,152,,,,,,,,,,-163 |
| 460 | M | V | 8.3 | 43,47,80,82,83,142,154,-156,159,-161,164,,,,-169 |
| 520 | H | Q | 10 | 47,72,83,142,154,155,159,161,164,165,169,-171 |
| 592 | C | G | 2.9 | 72,80,82,83,142,153,154,159,-161,163,165,166,172,173 |
| 594 | A | V | 8.3 | 43,72,80,82,83,152,,,-156,158,,-161,164,-166,171,173 |
| 595 | L | S | 9.2 | 43,72,80,82,83,153,-155,158,,,,,,,-166 |
| 603 | C | W | 8 | 72,80,83,142,153,-155,159,-161,163,164,171,172,174,175 |
| Other clinically relevant substitution mutations | ||||
| 595 | L | F | 15.7 | 72,156,161,175 |
| 595 | L | W | 5.1 | 72,154,155,159,-161,175 |
GCV ratio = IC50 of mutant/IC50 of wild-type (IC50 = 50% inhibitory concentration, the concentration at which there is a 50% reduction in the number of plaques on a phenotypic plaque reduction assay; GCV IC50 values ≤6 μM indicate sensitivity, and values >6 μM indicate resistance44 ).